$ILMN

Meister Keith A. sold $148.2M of ILMN (indirect holdings)

Meister Keith A. sold 741,127 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $199.91 ($196.74–$203.28, $148.16M total) across 14 trades over 2026-08-04 to 2026-08-05.

Original reporting
SEC EDGAR · Meister Keith A.
Published Aug 6, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 7:42 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ILMN
Neutral
medium confidence
Mentioned
$ILMN
Relevance
8/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

A director’s large open-market sale can influence short-term sentiment and options positioning, but the filing does not include any new company-specific performance, guidance, or regulatory developments.

02

Market read

Traders may monitor for follow-on selling or interpret the transaction as a sentiment signal, but there is no new fundamental catalyst in the text.

03

What to watch

Indirect holdings and multi-trade execution can reflect pre-planned personal tax or estate liquidity needs rather than a view on ILMN fundamentals.

Relevance 8/10Novelty 5/10Timing: filed Aug 6, covering sales on Aug 4-5

Background

This is an SEC Form 4 insider transaction disclosure for Illumina, Inc. (ILMN).

Company-level read

Ticker impact

$ILMNNeutralMedium confidence
Context

Illumina director Keith A. Meister sold $148.2M of ILMN via 14 open-market trades at $196.74 to $203.28, indirect holdings.

Expected impact

Likely limited, short-lived negative drift around insider-selling headlines; no direct guidance or business update is provided.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and a sizable notional, which can affect sentiment. However, the article contains no new operational, financial, or regulatory facts that would reprice fundamentals.

Market effects

Could marginally affect sentiment toward genomics tools/diagnostics peers if traders extrapolate insider risk, but no sector-wide catalyst is disclosed.

Primarily US large-cap sentiment; no cross-region linkage is provided.

No global macro or international transaction details are included.

Counterpoint

The sale may be routine liquidity or diversification, and the absence of a stated 10b5-1 plan does not necessarily imply negative company outlook.

Key entities

  • Illumina, Inc.

    Subject of the Form 4 insider sale; director Keith A. Meister reduced indirect holdings.

  • Meister Keith A.

    Director who sold 741,127 shares across 14 trades for about $148.16M.

Related articles

$ILMNHighAI 9/10

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Illumina (ILMN) reported Q2 2026 revenue of $1.16B, up 9.5% YoY, and non-GAAP EPS of $1.31. Clinical consumables and NovaSeq X placements drove results. Gross margin was 68.2%. Full-year 2026 guidance was raised to $4.60B-$4.64B revenue and $5.30-$5.40 EPS. Cash was $1.17B vs $1.99B debt.

$ILMNHighAI 9/10

Illumina (ILMN) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Conor McNamara Chief Executive Officer - Jacob Thaysen Chief Financial Officer - Ankur Dhingra TAKEAWAYS Total Revenue -- $1.16 billion, representing a 9.5% increase year over year driven by clinical market demand and the NovaSeq X expansion. Rest of World Organic Revenue -- Increased 8.1% year over year, exceeding the high end of management's previous guidance.

$ILMNMedAI 8/10

Illumina (NASDAQ:ILMN) Surprises With Q2 CY2026 Sales, Full

Genomics company Illumina (NASDAQ: ILMN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.62 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.31 per share was 6.8% above analysts’ consensus estimates. Is now the time to buy Illumina? Find out by accessing our full research report, it’s free.

$ILMNHigh

ILLUMINA, INC. (ILMN): Results of Operations and Financial Condition

ILLUMINA, INC. (ILMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q226earningsrelease.htm EX-99.1 Document Investors: Conor McNamara +1.858.291.6421 ir@illumina.com Media: Christine Douglass pr@illumina.com Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026 San Diego, July 30, 2026 /PRNewswire/ -- Illumina, Inc.